Floatz logo

Enzalutamide

Castration-Resistant Prostate Carcinoma

Prostate Cancer Clinical Trials ConsortiumSmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
73/ 100
Competitive Position
73/ 100

Competitive context

214 Active assets in the Castration-Resistant Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 4BBB
Prednisolone
Ding-Wei Ye
Phase 4BBB
Cabozantinib
Rana McKay, MD
Phase 3BB
RADIUM RA-223
University of California, San Francisco
Phase 4BB
Mevrometostat
Prostate Cancer Clinical Trials Consortium
Phase 3BB

View all 50 →

Same molecule, other indications

Enzalutamide is also rated in:

prostate carcinomaActive
BBB
Indicative · Phase 4
73 / 100
View asset →
breast carcinomaActive
BB
Indicative · Phase 2
68 / 100
View asset →
triple-negative breast carcinomaActive
BB
Indicative · Phase 2
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →